These results indicate that GABAergic antagonism can treat the locomotor hyperactivity and working memory defect in GAT1 KO mice, suggesting that antagonizing GABAergic activity may be a potential strategy for the therapy of schizophrenia. Here, SLC6A1 is linked to schizophrenia.